• 1
    Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay S, Powell J. Cancer incidence in five continents. IARC Scientific Publication, 1997.
  • 2
    Figge J. Epidemiology of thyroid cancer. A comprehensive guide to clinical management. In: Thyroid cancer. New Jersey: Humana Press, 2000. 7784.
  • 3
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297306.
  • 4
    UNSCEAR. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. UNSCEAR 2000. Report to the General Assembly, with scientific annexes. New York: United Nations, 2000.
  • 5
    Negri E, Ron E, Franceschi S, Dal Maso L, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Kleinerman R, Land C, Jin F, Wingren G, et al. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control 1999; 10: 13142.
  • 6
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 41828.
  • 7
    Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001; 11: 63745.
  • 8
    Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984; 23: 30513.
  • 9
    WHO. Histological typing of thyroid tumors. International histological classification of tumors. Berlin: Springer-Verlag, 1988.
  • 10
    Pettersson B, Adami H-O, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958–1981, by histopathologic type. Int J Cancer 1991; 48: 2833.
  • 11
    Henson DE, Ries LA. The relative survival rate. Cancer 1995; 76: 16878.
  • 12
    Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38: 93342.
  • 13
    Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed 1985; 19: 197207.
  • 14
    Greenwood M. The errors of sampling of the survivorship table. London: Her Majesty's Stationery Office, 1926.
  • 15
    Hakulinen T. On long-term relative survival rates. J Chronic Dis 1977; 30: 43143.
  • 16
    Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. Appl Stat 1987; 36: 30917.
  • 17
    Suissa S. Relative excess risk: an alternative measure of comparative risk. Am J Epidemiol 1999; 150: 27982.
  • 18
    WHO. Histological typing of thyroid tumors. International histological classification of tumors, no. 2. Geneva: WHO, 1974.
  • 19
    Pottern LM, Stone BJ, Day NE, Pickle LW, Fraumeni JF Jr. Thyroid cancer in Connecticut, 1935–1975: an analysis by cell type. Am J Epidemiol 1980; 112: 76474.
  • 20
    Magnusson C, Baron JA, Correira N, Bergström R, Adami H-O, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 33944.
  • 21
    La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L, Mabuchi K, Jin F, et al. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999; 10: 15766.
  • 22
    Mori M, Naito M, Watanabe H, Tekeichi N, Dohi K, Ito A. Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat, thyroid tumors. Cancer Res 1990; 50: 76627.
  • 23
    Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55: 794804.
  • 24
    Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 106375.
  • 25
    Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 46976.
  • 26
    Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program. Cancer 1997; 79: 56473.
  • 27
    Sautter-Bihl ML, Raub J, Hetzel-Sesterheim M, Heinze HG. Differentiated thyroid cancer: prognostic factors and influence of treatment on the outcome of 441 patients. Strahlenther Onkol 2001; 177: 12531
  • 28
    Raabe NK, Hagen S, Haug E, Fossaa SD. Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma. Int J Oncol 1998; 12: 10916.
  • 29
    Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, Kimura M, Tominaga T, Iino H, Morimoto T, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer 1992; 69: 15364